logo

INDOCO vs PANACEABIO: Stock Comparison

INDOCO REMEDIES vs PANACEA BIOTECUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

INDOCO REMEDIES is the larger company by market capitalisation. INDOCO REMEDIES shows a higher ROE, a higher dividend yield and faster revenue growth, while PANACEA BIOTEC shows a lower P/E and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

INDOCO leads 9; PANACEABIO leads 2 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

INDOCOPANACEABIO

Valuation lens

What price are you paying?

Market CapContext only
₹2,077 Cr
₹2,036 Cr
P/E RatioPANACEABIO has the lower reading
368.85x
0x ✓
P/B RatioINDOCO has the lower reading
2.21x ✓
2.44x
EPSINDOCO has the higher reading
₹7.04 ✓
₹0.38
Book ValueContext only
₹100.98
₹135.33
Dividend YieldINDOCO has the higher reading
0.09% ✓
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
INDOCO is the larger company
₹2,077 Cr vs ₹2,036 Cr
P/E Ratio
PANACEABIO has a lower P/E
0x vs 368.85x
P/B Ratio
INDOCO has a lower P/B
2.21x vs 2.44x
EPS
INDOCO has higher earnings per share
₹7.04 vs ₹0.38
Dividend Yield
INDOCO has a higher dividend yield
0.09% vs 0%
Revenue Growth (TTM YoY)
INDOCO has faster revenue growth
21.9% vs 1%
EPS Growth (TTM YoY)
INDOCO has faster EPS growth
0% vs -12.2%
ROE
INDOCO has a higher ROE
-0.51% vs -10.48%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINDOCOPANACEABIO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricINDOCOPANACEABIO
Live Price₹225.6₹326.8
Day Change-2.55%-3.74%
Volume1.07 L40,228
52-Week High₹291₹647
52-Week Low₹162.19₹292.4
Distance from 52W High-22.47%-49.49%

Valuation

MetricINDOCOPANACEABIO
Market Cap₹2,077 Cr₹2,036 Cr
P/E Ratio368.85x0x
P/B Ratio2.21x2.44x
EPS₹7.04₹0.38
Book Value₹100.98₹135.33
Dividend Yield0.09%0%

Growth

MetricINDOCOPANACEABIO
Revenue Growth (TTM YoY)21.9%1%
EPS Growth (TTM YoY)0%-12.2%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricINDOCOPANACEABIO
ROE-0.51%-10.48%
ROCE4.26%-3.39%
Net Margin-5.31%-0.84%
Operating Margin4.57%-4.49%
Debt to Equity0.64x0.93x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINDOCOPANACEABIO
Promoter Holding58.86%72.48%
FII Holding1.27%▲ 0.33 pp2.75%▲ 0.44 pp
DII Holding17.68%▼ 0.47 pp2.47%▲ 0.22 pp
Public Holding22.04%▲ 0.14 pp22.3%▼ 0.66 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INDOCO REMEDIES and PANACEA BIOTEC.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.